A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

← catalyst calendar

NCT07749586 · readout in 1,685 d

Sponsored by Arvinas Inc. (industry) · ARVN — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

499estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-29

actual

When the study began enrolling

Primary completion

2031-03-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2032-03-31

estimated

The whole study's end, after follow-up

First posted

2026-08-06

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-06

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Advanced Solid Tumor

Interventions

Drug: ARV-6723
Drug: Pembrolizumab
Drug: SOC

Primary outcomes

what the primary-completion date above is the date OF

Part A1: Number of Dose-Limiting Toxicities (DLTs) of ARV-6723

measured 21 days from first ARV-6723 administration

Part A1: Number of Participants With Adverse Events (AEs)

measured From the first dose of ARV-6723 through at least 28 days after the last dose (up to approximately 4.7 years)

Part A2: Number of Participants With AEs

measured From the first dose of ARV-6723 through at least 28 days after the last dose (up to approximately 4.7 years)

Part A2: Overall Response Rate (ORR) by computed tomography/magnetic resonance imaging (CT/MRI) Using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) Criteria Per Investigator Assessment

measured Approximately 24 months

Part B: ORR by CT/MRI using RECIST v1.1 Criteria Per Investigator Assessment

measured Approximately 24 months

Permalink · ARVN's whole pipeline · Catalyst calendar · Every registered study · What changed